Pregnancy Drug Makena Removed From Market Amid Concerns About Lack of Benefits Preventing Premature Birth, Unnecessary Risks for Women

Experts have determined the pregnancy drug Makena provides little to no benefit and puts pregnant mothers and their children at risk of adverse health events.

After years of debate about whether expecting mothers experience any benefits from Makena, a medication used to prevent premature birth, the manufacturer have agreed to remove the drug from the market, since it appears to expose women to unnecessary risks.

Clovis Pharma announced plans to remove Makena from the market in a letter to the U.S. Food and Drug Administration (FDA) on March 6, based on the findings of an FDA scientific advisory panel, which recently determined the medication has a non-favorable safety profile based on data from post marketing trials.

Makena (hydroxyprogesterone) was first introduced in 2011, and is the only medication approved for prevention of preterm birth among women who had a prior spontaneous premature delivery. Being the first of its kind treatment, with a high demand, the drug received approval through the FDA’s accelerated approval process based on positive findings from a placebo-controlled trial that involved only 463 participants.

However, critics have been calling for a Makena recall after later data suggested the drug simply does not work, with some clinical trial data even suggesting Makena could worsen conditions commonly experienced by pregnant women, including preeclampsia and depression. Despite the mounting evidence against the drug’s effectiveness and safety, the manufacturer Covis Pharma, vowed to fight any Makena recall attempt.

There were no signs that the drug maker intended to issue a Makena recall until October 2022, when the Obstetrics, Reproductive and Urologic Drugs Advisory Committee held a three-day hearing to discuss the efficacy of Makena, and voted 14 to 1 to recommend the FDA remove Makena from the market. The Committee also voted unanimously (15 to 0) to recognize that the postmarketing Makena trials did not show any benefit to babies. Following the recommendation, the FDA gave Covis Pharma until March 6 to submit comments for consideration on the withdraw recommendation.

Before Covis issued its official response, the FDA’s Center for Drug Evaluation and Research (CDER) issued yet another Proposal To Remove Makena, and its generic equivalents from the market. The CDER’s proposal gave a strong recommendation to immediately withdraw Makena after an independent review of the postmarketing trials, stating the drug “unnecessarily exposes patients to only risks” and “would be contrary to public health.”

On March 6, Covis Pharma acquiesced. In a response letter sent to the FDA this month, Covis Pharma maintains that Makena has a favorable risk-benefit profile for individuals, but has agreed to voluntarily remove Makena from the market over what they called a “wind-down” period.

The manufacturer stated that an abrupt stoppage of Makena would be disruptive to patients in the middle of the drugs 21 week course. Therefore, the manufacturer has suggested the FDA set an effective date to end sales of Makena and its generic versions, while allowing anyone in the process of a prescription treatment of Makena to finish the 21 week cycle.

Makena Side Effects

In early October 2019, the consumer watchdog group Public Citizen called for a Makena recall in an FDA petition, saying it did not make sense for the synthetic hormone to remain on the market to be injected into pregnant women, who would then face the risk of side effects without any apparent benefits.

Makena concerns have grown since the release of a clinical trial, Progestin’s Role in Optimizing Neonatal Gestation (PROLONG), which found Makena side effects may increase the risk of pulmonary embolism, blood clots, allergic reactions, decreased glucose intolerance, fluid retention, as well as worsening preeclampsia and depression symptoms.

Preliminary findings of a study presented in 2021, at the annual meeting of The Endocrine Society, suggested children born to women who received Makena which contains hydroxyprogesterone caproate, also known as OHPC or 17-OHPC, had upward of five times the risk of developing colon and rectal cancers when compared to the children of mothers who did not take the drug.